Immunovant, Inc. (IMVT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$28.41-2.37%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Immunovant, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	7.1M
EPS	—	-0.729
Annual ending 2027-03-31
Revenue	—	6.64M
EPS	—	-2.936
Annual ending 2028-03-31
Revenue	—	42.94M
EPS	—	-2.919

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Positive clinical trial results for IMVT-1402	Positive trial data boosts confidence.	Intact	Negative trial results or regulatory setbacks occur	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce losses and improve earnings per share	A primary condition in Immunovant, Inc.'s published investment case. The stated target is EPS loss narrows from -$2.44 in FY27 to less negative in FY28.	Intact	EPS loss worsens beyond -$2.44 in FY28	Diluted EPS: $-0.75 per share FY2027-Q1; GAAP. Published target: EPS loss narrows from -$2.44 in FY27 to less negative in FY28. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.75 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b5008448-7cea-4474-b314-172fa25fb641. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stable leadership and R&D team	A supporting condition in Immunovant, Inc.'s published investment case. The stated target is No further key executive departures through FY27.	Intact	Loss of key executives or R&D disruption	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Start generating meaningful revenue from product sales	A primary condition in Immunovant, Inc.'s published investment case. The stated target is Achieve >$37 million revenue in FY28.	Intact	Revenue falls below $20 million in FY28	Revenue: $7.095M FY2027-Q1; GAAP. Published target: Achieve >$37 million revenue in FY28. Target period is not explicitly aligned with this observation. Source published Aug 6, 20267,095,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2027-Q1. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-03-31 · fmp

FY2028 EPS$-2.92

$-2.59 → $-2.92 · observed estimates

FY2028 revenue$0.04B

$0.06B → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.59	$59,489,609	8 / 9
2026-07-25	$-2.59	$59,489,609	8 / 9
2026-07-26	$-2.59	$59,489,609	8 / 9
2026-07-27	Unavailable	$39,659,740	3 / 12
2026-07-28	Unavailable	$39,659,740	3 / 12
2026-07-29	Unavailable	$39,659,740	3 / 12
2026-07-30	Unavailable	$39,659,740	3 / 12
2026-07-31	Unavailable	$36,608,990	4 / 13
2026-08-01	$-2.58	$52,879,652	7 / 8
2026-08-02	Unavailable	$36,608,990	4 / 13
2026-08-03	Unavailable	$36,608,990	4 / 13
2026-08-04	Unavailable	$36,608,990	4 / 13
2026-08-05	$-2.58	$52,879,652	8 / 9
2026-08-06	$-2.58	$52,879,652	8 / 9
2026-08-07	$-2.69	$48,541,687	9 / 9
2026-08-08	$-2.69	$48,541,687	9 / 9
2026-08-09	$-2.33	$33,994,060	5 / 14
2026-08-10	$-2.69	$48,541,687	9 / 9
2026-08-12	$-2.69	$48,541,687	9 / 9
2026-08-13	$-2.69	$48,541,687	9 / 9
2026-08-14	$-2.69	$48,541,687	9 / 9
2026-08-15	$-2.69	$48,541,687	9 / 9
2026-08-16	$-2.69	$48,541,687	9 / 9
2026-08-17	$-2.69	$48,541,687	9 / 9
2026-08-18	$-2.69	$48,541,687	9 / 9
2026-08-19	$-2.69	$48,541,687	9 / 9
2026-08-20	$-2.80	$44,128,806	8 / 9
2026-08-21	$-2.80	$44,128,806	8 / 9
2026-08-22	$-2.80	$44,128,806	8 / 9
2026-08-23	$-2.89	$46,845,010	8 / 9
2026-08-24	$-2.89	$46,845,010	8 / 9
2026-08-25	$-2.92	$42,941,259	8 / 9
2026-08-26	$-2.92	$42,941,259	9 / 9
2026-08-27	$-2.92	$42,941,259	9 / 9
2026-08-28	$-2.92	$42,941,259	9 / 9
2026-08-29	$-2.92	$42,941,259	8 / 9
2026-08-30	$-2.92	$42,941,259	8 / 9
2026-08-31	$-2.92	$42,941,259	8 / 9
2026-09-01	$-2.92	$42,941,259	8 / 9
2026-09-02	$-2.92	$42,941,259	8 / 9
2026-09-03	$-2.92	$42,941,259	8 / 9
2026-09-04	$-2.92	$42,941,259	8 / 9
2026-09-05	$-2.92	$42,941,259	8 / 9
2026-09-06	$-2.92	$42,941,259	8 / 9
2026-09-07	$-2.92	$42,941,259	8 / 9
2026-09-08	$-2.92	$42,941,259	8 / 9
2026-09-09	$-2.92	$42,941,259	8 / 9
2026-09-10	$-2.92	$42,941,259	8 / 9
2026-09-11	$-2.92	$42,941,259	8 / 9
2026-09-12	$-2.92	$42,941,259	8 / 9
2026-09-13	$-2.92	$42,941,259	8 / 9
2026-09-14	$-2.92	$42,941,259	8 / 9
2026-09-15	$-2.92	$42,941,259	8 / 9
2026-09-16	$-2.92	$42,941,259	8 / 9
2026-09-17	$-2.92	$42,941,259	8 / 9
2026-09-18	$-2.92	$42,941,259	8 / 9
2026-09-19	$-2.92	$42,941,259	8 / 9
2026-09-20	$-2.92	$42,941,259	8 / 9
2026-09-21	$-2.92	$42,941,259	8 / 9
2026-09-22	$-2.92	$42,941,259	8 / 9
2026-09-23	$-2.92	$42,941,259	8 / 9
2026-09-24	$-2.92	$42,941,259	8 / 9
2026-09-25	$-2.92	$42,941,259	8 / 9
2026-09-26	$-2.92	$42,941,259	8 / 9
2026-09-27	$-2.92	$42,941,259	8 / 9
2026-09-28	$-2.92	$42,941,259	8 / 9
2026-09-29	$-2.92	$42,941,259	8 / 9
2026-09-30	$-2.92	$42,941,259	8 / 9
2026-10-01	$-2.92	$42,941,259	8 / 9
2026-10-02	$-2.92	$42,941,259	8 / 9
2026-10-03	$-2.92	$42,941,259	8 / 9
2026-10-04	$-2.92	$42,941,259	8 / 9
2026-10-05	$-2.92	$42,941,259	8 / 9
2026-10-06	$-2.92	$42,941,259	8 / 9
2026-10-07	$-2.92	$42,941,259	8 / 9
2026-10-08	$-2.92	$42,941,259	8 / 9
2026-10-09	$-2.92	$42,941,259	8 / 9
2026-10-10	$-2.92	$42,941,259	8 / 9
2026-10-11	$-2.92	$42,941,259	8 / 9
2026-10-12	$-2.92	$42,941,259	8 / 9
2026-10-13	$-2.92	$42,941,259	8 / 9
2026-10-14	$-2.92	$42,941,259	8 / 9
2026-10-15	$-2.92	$42,941,259	8 / 9
2026-10-16	$-2.92	$42,941,259	8 / 9
2026-10-17	$-2.92	$42,941,259	8 / 9
2026-10-18	$-2.92	$42,941,259	8 / 9
2026-10-19	$-2.92	$42,941,259	8 / 9
2026-10-20	$-2.92	$42,941,259	8 / 9
2026-10-21	$-2.92	$42,941,259	8 / 9
2026-10-22	$-2.92	$42,941,259	8 / 9
2026-10-23	$-2.92	$42,941,259	8 / 9
2026-10-24	$-2.92	$42,941,259	8 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	13	5
2026-06-01	13	5
2026-07-01	13	5
2026-08-01	13	4
2026-09-01	13	4
2026-10-01	13	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Positive clinical trial results for IMVT-1402Direct metric needs a verified mapping
Reduce losses and improve earnings per shareDiluted EPS: $-0.75 per share
Stable leadership and R&D teamDirect metric needs a verified mapping
Start generating meaningful revenue from product salesRevenue: $7.095M

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-40.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Immunovant, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-development exposure, not a proven earnings compounder. The multi-year view is on watch: management says IMVT-1402 timelines remain on track, but the evidence snapshot gives low confidence and recent financial performance is weak.

What's priced into Immunovant, Inc.

The evidence provides no valuation measure or direct account of market expectations, so whether the shares are cheap, fair, or expensive versus peers cannot be assessed. The snapshot does flag weak performance relative to the industry cohort, but that alone does not show what expectations are already reflected.

What the fundamentals likely do

Near term, consecutive earnings misses and an elevated risk of another miss make results a key concern. Over the multi-year view, management reports clinical timelines on track across six indications, with topline data expected from 2026 through 2028; cash declined between the first and second quarters of 2026. The sector backdrop is a tailwind, but the evidence for near-term operating improvement is thin.

What Immunovant, Inc. hinges on

The thesis depends on IMVT-1402 advancing on schedule and producing useful data across its indications, alongside adequate resources for a potential Graves' disease launch. A guidance cut or further weak results would add concern, while continued strength among healthcare bellwethers could support the sector backdrop.